

## Accepted Manuscript

Total syntheses of (+)-bernumidine and its unnatural enantiomer

Bianca K. Corrêa, Tamiris R.C. Silva, Cristiano Raminelli

PII: S0040-4039(18)31047-5  
DOI: <https://doi.org/10.1016/j.tetlet.2018.08.046>  
Reference: TETL 50221

To appear in: *Tetrahedron Letters*

Received Date: 12 July 2018  
Revised Date: 14 August 2018  
Accepted Date: 22 August 2018



Please cite this article as: Corrêa, B.K., Silva, T.R.C., Raminelli, C., Total syntheses of (+)-bernumidine and its unnatural enantiomer, *Tetrahedron Letters* (2018), doi: <https://doi.org/10.1016/j.tetlet.2018.08.046>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


## Graphical Abstract

To create your abstract, type over the instructions in the template box below.  
Fonts or abstract dimensions should not be changed or altered.

### Total syntheses of (+)-bernumidine and its unnatural enantiomer

Bianca K. Corrêa, Tamiris R. C. Silva, Cristiano Raminelli\*

Leave this area blank for abstract info.





Tetrahedron Letters  
journal homepage: [www.elsevier.com](http://www.elsevier.com)

## Total syntheses of (+)-bernumidine and its unnatural enantiomer

Bianca K. Corrêa, Tamiris R. C. Silva, Cristiano Raminelli\*

Instituto de Ciências Ambientais, Químicas e Farmacêuticas, Universidade Federal de São Paulo, Rua Prof. Artur Riedel, 275, Diadema 09972-270, SP, Brazil

### ARTICLE INFO

#### Article history:

Received

Received in revised form

Accepted

Available online

#### Keywords:

(+)-Bernumidine

Bernumidine enantiomer

MOR ligands

Chemoenzymatic DKR

Enantioselective hydrogenation

### ABSTRACT

Total syntheses of (+)-bernumidine and its unnatural enantiomer were accomplished through chemoenzymatic dynamic kinetic resolution and ruthenium(II)-catalyzed enantioselective hydrogenation, which provided (*R*)-salsolidine propyl carbamate and *N*-acetyl (*S*)-salsolidine in high yields and enantiomeric excesses, respectively. Both enantiomers of salsolidine were accessed and converted into (+)- and (-)-bernumidine *via* simple and efficient transformations.

2009 Elsevier Ltd. All rights reserved.

(+)-Bernumidine (**1a**) is an benzyloisoquinoline alkaloid isolated for the first time from leaves of *Berberis nummularia*<sup>1</sup> and (-)-bernumidine (**1b**) is its unnatural enantiomer.<sup>2</sup> Although plants of the genus *Berberis* have been employed for centuries throughout the world because of tonic, antimicrobial, and sedative properties,<sup>2,3</sup> to the best of our knowledge, no research concerning biological activities for (+)-bernumidine (**1a**) or even for (-)-bernumidine (**1b**) has been published until the present moment. Nevertheless, a recent study has disclosed that a racemic bernumidine derivative, i.e., where the piperonyl moiety was changed by 4-hydroxy-3,5-dimethylbenzyl group, was identified as a novel chemical scaffold with binding affinity to the  $\mu$  opioid receptor (MOR) *in vitro*, combined with MOR antagonist properties. Moreover, *in vivo*, the same substance has been highly effective in antagonizing morphine-induced antinociception in mice.<sup>4</sup> Despite the important discoveries involving a bernumidine derivative in medicinal chemistry,<sup>4</sup> in preparative organic chemistry we realized a lack of synthetic routes to produce both enantiomers of bernumidine (**1a** and **1b**). In 2001, the synthesis of racemic bernumidine was reported by Vallée and coworkers through the alkylation of racemic salsolidine.<sup>2</sup> In that article, authors also resolved racemic salsolidine by precipitating one of the enantiomers with D-(-)-tartaric acid, further performing the alkylation of the enantiomer


isolated to provide (+)-bernumidine (**1a**). However, there is no synthesis of (-)-bernumidine (**1b**) reported so far. Accordingly, enantioselective approaches for the syntheses of (+)-bernumidine (**1a**) and (-)-bernumidine (**1b**), which could be employed in the preparation of both enantiomers of a variety of bernumidine derivatives, would be of considerable importance. Thus, we examined the literature and found a practical, scalable, and efficient chemoenzymatic dynamic kinetic resolution (DKR) of secondary amines using an iridium-based amine racemization catalyst under significantly mild conditions, which was employed to the formation of (*R*)-salsolidine propyl carbamate in high yield and enantiomeric excess.<sup>5</sup> In addition, the operationally refined enantioselective hydrogenation of enamides catalyzed by BINAP-ruthenium(II) complexes was the method of choice to obtain *N*-acetyl (*S*)-salsolidine also in high yield and enantiomeric excess.<sup>6</sup>

In our retrosynthetic analysis (+)-bernumidine (**1a**) and its unnatural enantiomer (**1b**) are obtained from (*R*)-salsolidine (**2a**) and (*S*)-salsolidine (**2b**), which are produced from valuable approaches employing isoquinoline intermediates **5** and **6**, respectively, both obtained from 3,4-dimethoxyphenethylamine (**7**) (Scheme 1).

\* Corresponding author. Tel.: +55-11-4044-0500 (extension line: 3473); fax: +55-11-4043-6428; e-mail: [raminelli@unifesp.br](mailto:raminelli@unifesp.br)


Intermediates **5** and **6** were prepared by minor modifications of well-established reactions.<sup>7-10</sup> Commercially available 3,4-dimethoxyphenethylamine (**7**) was treated with acetic anhydride in pyridine to produce corresponding *N*-(3,4-dimethoxyphenethyl)acetamide (**8**) in 97% yield.<sup>7</sup> Acetamide **8** was converted by Bischler-Napieralski reaction to heterocyclic compound **9** in 94% yield.<sup>8</sup> Intermediate **9** was reduced in the presence of NaBH<sub>4</sub> leading to 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (**5**) in 74% isolated yield.<sup>9</sup> Afterwards, intermediate **9** was also allowed to react with acetic anhydride in pyridine leading to the formation of 1-(6,7-dimethoxy-1-methylene-3,4-dihydroisoquinolin-2(1*H*)-yl)ethenone (**6**) in 88% isolated yield<sup>10</sup> (Scheme 2).

Intermediate **6** was asymmetrically reduced employing hydrogen (20 atm) and (*S*)-Ru(AcO)<sub>2</sub>(BINAP) (2.7 mol%) as catalyst in ethanol/dichloromethane (5:1) at room temperature for 72 h to produce (*S*)-salsolidine acetate (**12**) in 94% isolated yield and with 90% ee<sup>6</sup> (**Scheme 4**).



The scheme shows the conversion of compound **6** to **12** and then to **2b**.
   
 Step 1: Compound **6** (a 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivative with an exocyclic methylene group and a methyl ketone) reacts with  $\text{H}_2$  (20 bar) in the presence of a  $(S)\text{-Ru}(\text{AcO})_2(\text{BINAP})$  catalyst (2.7 mol%) in  $\text{EtOH}/\text{CH}_2\text{Cl}_2$  (5:1) at room temperature for 72 hours to yield compound **12** (a 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivative with a methyl ketone and a methyl group at the 3-position) in 94% yield and 90% ee.
   
 Step 2: Compound **12** is treated with  $\text{LiOH} \cdot \text{H}_2\text{O}$  (10 equiv.) in  $\text{EtOH}/\text{H}_2\text{O}$  (2:1) under microwave irradiation (90 W) at 180 °C for 1 hour to yield compound **2b** (a 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivative with a methyl group at the 3-position) in 85% yield.


Intermediate **5** was treated with 3-methoxyphenylpropyl carbonate (**10**)<sup>5b</sup> employing [IrCp\*I<sub>2</sub>]<sub>2</sub><sup>5b,c</sup> (0.2 mol%) and *Candida rugosa* lipase (1117 U/mg) as catalysts in toluene saturated with water at 40 °C for 48 h to produce (*R*)-salsolidine propyl carbamate (**11**) in 68% isolated yield and with 99% ee<sup>5</sup> (**Scheme 3**).



Asymmetric reduction of intermediate **6** provided (*S*)-salsolidine acetate (**12**) employing 20 atm pressure of hydrogen for 72 h under strictly inert atmosphere and anhydrous conditions. According to previous report,<sup>6</sup> the reduction of intermediate **6** gave (*S*)-salsolidine acetate (**12**) in 100% conversion and with 96% ee employing 4 atm pressure of hydrogen for 48 h also under strictly inert atmosphere and anhydrous conditions. Subsequently, (*S*)-salsolidine acetate (**12**) was hydrolyzed using LiOH·H<sub>2</sub>O in a mixture of ethanol/water (2:1) under microwave heating (90 W) at 180 °C for 1 h,<sup>11</sup> affording (*S*)-salsolidine (**2b**) in 85% (**Scheme 4**).

Although chemoenzymatic DKR represents a practical, scalable, and efficient transformation to produce (*R*)-salsolidine propyl carbamate (**11**) only this enantiomer can be accessed through this approach.<sup>5</sup> In spite of the ruthenium(II)-catalyzed enantioselective hydrogenation may be considered operationally laborious, this method can be used to produce (*S*)-salsolidine acetate (**12**) and also its enantiomer just by changing the chiral BINAP ligand employed.<sup>6</sup>

Piperonyl alcohol (**4**) was converted to piperonyl bromide (**3**) using  $\text{PBr}_3$  in 86% yield.<sup>12</sup> Then, (*R*)-salsolidine (**2a**) and (*S*)-salsolidine (**2b**) were allowed to react with piperonyl bromide (**3**) in the presence of  $\text{K}_2\text{CO}_3$ , under extensively optimized conditions, which were achieved performing the transformation in different temperatures and times, using conventional and microwave heating, leading to (+)-bernumidine (**1a**) and (-)-bernumidine (**1b**), respectively, both in an isolated yield of 85% (Scheme 5).



**Scheme 5.** Transformations to achieve (+)-bernumidine (**1a**) and (-)-bernumidine (**1b**).

(+)-Benumidine (**1a**) and (-)-bernumidine (**1b**) were obtained after 6 steps with overall yields of 39% and 54%, respectively. Furthermore, both enantiomers of bernumidine (**1a** and **1b**) were achieved through short and efficient routes with enantiomeric excesses  $\geq 90\%$ .

The structures of compounds **2a,b** and **3-12** were assigned according to their LRMS, IR,  $^1\text{H}$ , and  $^{13}\text{C}$  NMR spectra. DEPT 135, COSY, and HSQC NMR spectra were obtained to confirm the structure of compound **11**. The structures of compounds **1a,b** were assigned according to their LRMS, IR,  $^1\text{H}$ ,  $^{13}\text{C}$ , DEPT 135, COSY, and HSQC NMR spectra. Compound **1b** provided HRMS that is in agreement with the proposed structure. The optical rotation of compound **1a** matched the one reported for the natural bernumidine<sup>1</sup> (Supporting Information).

In summary, total syntheses of (+)-bernumidine and its unnatural enantiomer were accomplished through chemoenzymatic dynamic kinetic resolution and ruthenium(II)-catalyzed enantioselective hydrogenation, respectively. Chemoenzymatic DKR represents a practical, scalable, and efficient transformation to produce (*R*)-salsolidine propyl carbamate, however, only this enantiomer can be accessed through this method. Although ruthenium(II)-catalyzed enantioselective hydrogenation may be considered operationally laborious, this approach can be used to produce (*S*)-salsolidine acetate (**12**) and also its enantiomer. Short and efficient routes were developed for both enantiomers of bernumidine (**1a** and **1b**) and we expect that these routes may be employed for the preparation of bernumidine derivatives with application in medicinal chemistry.

## Acknowledgments

We are grateful to São Paulo Research Foundation (FAPESP) (Grant Number: 2017/21990-0) and to National Council for Scientific and Technological Development (CNPq) for financial support. B.K.C. and T.R.C.S. thank Coordination of Improvement of Higher Level Personnel (CAPES) for the fellowships.

## References and notes

1. Karimov, A.; Shakirov, R. *Chem. Nat. Compd.* **1993**, 29, 335.
2. Pinet, S.; Chavant, P. Y.; Averbuch-Pouchot, M.-T.; Vallée, Y. *J. Chem. Research (S)* **2001**, 65.
3. Mokhber-Dezfuli, N.; Saeidnia, S.; Gohari, A. R.; Kurepaz-Mahmoodabadi, M. *Pharmacogn. Rev.* **2014**, 8, 8.
4. Kaserer, T.; Lantero, A.; Schmidhammer, H.; Spetea, M.; Schuster, D. *Sci. Rep.* **2016**, 6, 21548.
5. (a) Verho, O.; Bäckvall, J.-E. *J. Am. Chem. Soc.* **2015**, 137, 3996. (b) Blacker, A. J.; Stirling, M. J.; Page, M. I. *Org. Process Res. Dev.* **2007**, 11, 642. (c) Stirling, M.; Blacker, J.; Page, M. I. *Tetrahedron Lett.* **2007**, 48, 1247.
6. (a) Kitamura, M.; Tsukamoto, M.; Bessho, Y.; Yoshimura, M.; Kobs, U.; Widhalm, M.; Noyori, R. *J. Am. Chem. Soc.* **2002**, 124, 6649. (b) Kitamura, M.; Hsiao, Y.; Ohta, M.; Tsukamoto, M.; Ohta, T.; Takaya, H.; Noyori, R. *J. Org. Chem.* **1994**, 59, 297. (c) Noyori, R.; Ohta, M.; Hsiao, Y.; Kitamura, M. *J. Am. Chem. Soc.* **1986**, 108, 7117.
7. (a) Moreno, L.; Cabedo, N.; Boulangé, A.; Parraga, J.; Galán, A.; Leleu, S.; Sanz, M.-J.; Cortes, D.; Franck, X. *Eur. J. Med. Chem.* **2013**, 69, 69. (b) Liu, D.; Venhuis, B. J.; Wikström, H. V.; Dijkstra, D. *Tetrahedron* **2007**, 63, 7264.
8. (a) Brossi, A.; Dolan, L. A.; Teitel, S. *Org. Synth.* **1988**, 6, 1. (b) Whaley, W. M.; Govindachari, T. R. *Org. React.* **1951**, 6, 74. (c) Kürti, L.; Czákó, B. *Strategic Applications of Named Reactions in Organic Synthesis*; Elsevier Academic Press: San Diego, 2005; pp 62.
9. (a) Lee, K. M.; Kim, J. C.; Kang, P.; Lee, W. K.; Eum, H.; Ha, H.-J. *Tetrahedron* **2012**, 68, 883. (b) Cho, B. T.; Kang, S. K. *Tetrahedron* **2005**, 61, 5725.
10. (a) Leroy, C.; Dupas, G.; Bourguignon, J.; Quéguiner, G. *Tetrahedron* **1994**, 50, 13135. (b) Atanes, N.; Castelo, L.; Guitián, E.; Saá, C.; Saá, J. M.; Suau, R. *J. Org. Chem.* **1991**, 56, 2984. (c) Gómez, B.; Martín, G.; Guitián, E.; Castedo, L.; Saá, J. M. *Tetrahedron* **1993**, 49, 1251.
11. (a) Muraca, A. C. A.; Perecim, G. P.; Rodrigues, A.; Raminelli, C. *Synthesis* **2017**, 49, 3546. (b) Perecim, G. P.; Rodrigues, A.; Raminelli, C. *Tetrahedron Lett.* **2015**, 56, 6848.
12. Angle, S. R.; Choi, I.; Tham, F. S. *J. Org. Chem.* **2008**, 73, 6268.

## Supplementary Material

Supplementary data (experimental procedures, characterization data, and RMN spectra) associated with this article can be found, in the online version, at <http://dx.doi.org/XXX>.

**Highlights**

- Synthetic routes were developed for (+)-bernumidine and its unnatural enantiomer.
- Total synthesis of (+)-bernumidine was accomplished through chemoenzymatic DKR.
- Bernumidine unnatural enantiomer was achieved via enantioselective hydrogenation.